Santen Pharmaceutical Co., Ltd.

MUN:SZD0 Stock Report

Market Cap: €3.3b

Santen Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Santen Pharmaceutical's earnings have been declining at an average annual rate of -8.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 5.5% per year. Santen Pharmaceutical's return on equity is 9.1%, and it has net margins of 8.6%.

Key information

-8.5%

Earnings growth rate

-5.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate5.5%
Return on equity9.1%
Net Margin8.6%
Next Earnings Update06 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Santen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

MUN:SZD0 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24302,56326,12486,31023,899
30 Jun 24304,34726,85387,58324,619
31 Mar 24301,96526,63487,27025,416
31 Dec 23302,08427,714133,319-3,474
30 Sep 23295,92826,364134,950-1,806
30 Jun 23285,893-11,205135,711-798
31 Mar 23279,037-14,955134,0720
31 Dec 22270,242-8,195125,7892,879
30 Sep 22266,413-9,133123,2541,929
30 Jun 22266,80426,533119,590979
31 Mar 22266,25727,212120,6100
31 Dec 21263,6205,056121,0881,150
30 Sep 21259,4597,319119,9961,215
30 Jun 21257,0287,978118,482504
31 Mar 21249,6056,826113,5860
31 Dec 20241,01524,430106,585500
30 Sep 20241,68524,279106,419-289
30 Jun 20239,98223,404106,103-558
31 Mar 20241,55523,616106,5990
31 Dec 19243,14228,876103,63162
30 Sep 19238,45730,721101,968448
30 Jun 19236,67931,498101,894555
31 Mar 19234,02631,953102,0200
31 Dec 18229,56031,291101,646-804
30 Sep 18228,51234,370101,724-778
30 Jun 18225,47733,083101,0436
31 Mar 18224,94235,24799,9260
31 Dec 17217,02130,58065,85524,751
30 Sep 17212,04125,71763,87224,224
30 Jun 17205,03824,75661,89023,241
31 Mar 17199,09623,06160,93422,786
31 Dec 16196,75423,29959,89821,636
30 Sep 16195,24722,31759,53221,051
30 Jun 16197,32253,15559,16920,561
31 Mar 16195,29153,37358,38219,990
31 Dec 15194,19357,72940,10731,761
30 Sep 15187,77958,59043,52426,720
30 Jun 15176,12427,84246,68122,064
31 Mar 15161,83124,03248,07417,477
31 Dec 14156,55917,92352,39819,040
30 Sep 14151,32517,21448,59719,040
30 Jun 14148,03115,27845,81219,040
31 Mar 14148,66317,10944,10419,040
31 Dec 13139,58717,76040,80816,719

Quality Earnings: SZD0 has a large one-off loss of ¥14.8B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: SZD0's current net profit margins (8.6%) are lower than last year (8.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SZD0's earnings have declined by 8.5% per year over the past 5 years.

Accelerating Growth: SZD0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SZD0 had negative earnings growth (-0.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).

Return on Equity

High ROE: SZD0's Return on Equity (9.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:12
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Philip HallBNP Paribas Securities (Asia)
Koichi MameganoBofA Global Research